Budapest, Hungary

Miklos Riesz, Deceased

This inventor holds 1 USPTO granted patent. Top assignee: Richter Gedeon Vegyeszeti Gyar Rt. Active years: 1995.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Miklos Riesz, Deceased. Retrieved from https://idiyas.com/inventor/miklos-riesz-deceased

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 1995

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Miklos Riesz: A Legacy in Pharmaceutical Innovation

Introduction

Miklos Riesz was a notable inventor in the field of pharmaceuticals, recognized for his contributions to muscle relaxant compounds. His work has had a lasting impact on medical science, particularly in the development of curare-like muscle relaxants.

Latest Patents

Riesz held a patent for "Diamino-androstane derivatives," which includes new monoquaternary and diquaternary 5-alpha-hydroxy-3,16-diaminoandrostane salts. These salts are characterized by their surprisingly rapid onset time and exhibit muscle relaxant activity similar to curare.

Career Highlights

Throughout his career, Riesz was associated with Richter Gedeon Vegyeszeti Gyar Rt., a prominent pharmaceutical company. His innovative work in drug development has contributed significantly to advancements in therapeutic options for patients.

Collaborations

Riesz collaborated with esteemed colleagues such as Zoltan Tuba and Judit Horvath, further enhancing the scope and impact of his research.

Conclusion

Miklos Riesz's contributions to the field of pharmaceuticals, particularly through his patented innovations, have left a significant mark on medical science. His legacy continues to inspire future generations of inventors and researchers.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…